Circulating T-cell receptor diversity as predictive biomarker for PARP inhibitors maintenance therapy in high grade serous ovarian cancer

ElsevierVolume 168, January 2023, Pages 135-143Gynecologic OncologyAuthor links open overlay panelHighlights•

The TCR repertoire was more stable in patients with high grade serous ovarian cancer following PARPi maintenance therapy.

An increase in TCR diversity after three months of PARPi maintenance may predict a better response to PARPi treatment.

Patients who responded better to PARPi treatment showed a decrease of high-frequency TCR clones.

AbstractObjective

T-cell receptor (TCR) repertoire diversity is getting increasing attention as a predictive biomarker in cancer patients. However, the characteristics of the TCR together with its predictive significance for high grade serous ovarian cancer (HGSOC) patients receiving poly (ADP-ribose) polymerase inhibitor (PARPi) maintenance therapy remain unknown.

Methods

Twenty-seven patients with HGSOC were analyzed including 22 patients receiving PARPi maintenance therapy and 5 untreated patients as control. Peripheral blood samples were collected for TCR sequencing at baseline as well as one month and three months after the exposure to PARPi. To determine whether TCR diversity was related to PARPi efficacy, we compared the TCR repertoire between patients who had received PARPi and those who had not.

Results

For patients receiving PARPi treatment or not, we evaluated changes in clone abundance during PARPi maintenance and the similarity of the TCR repertoire before and after the treatment. The results revealed that patients receiving PARPi had TCR repertoires that were more stable than those of untreated cases. We next correlated TCR diversity with the efficacy of PARPi in the treatment group. The rising trend of TCR diversity after three months with PARPi treatment was associated with a longer PFS (21.7 vs 7.4 months, hazard ratio = 0.19, p < 0.001) and a better response to PARPi (91.7% vs 25.0%, p = 0.004). Furthermore, we discovered that the primary characteristic with predictive value for the effectiveness of PARPi is the considerable reduction of the high-frequency T cell clones.

Conclusion

We suggested that the circulating TCR diversity could be a potential predictive biomarker for PARPi maintenance therapy in HGSOC.

Keywords

Ovarian cancer

TCR diversity

PARP inhibitor

Maintenance therapy

Predictive biomarker

View full text

© 2022 Published by Elsevier Inc.

留言 (0)

沒有登入
gif